Diffusion Pharmaceuticals Stock Price

-0.0428 (-4.69%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Diffusion Pharmaceuticals Inc DFFN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0428 -4.69% 0.87 00:00:04
Close Price Low Price High Price Open Price Previous Close
0.851 0.85 0.9299 0.929 0.9128
Bid Price Ask Price Spread News
0.855 0.90 0.045 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
2,260 1,045,535 $ 0.8891778 $ 929,667 1,410,299 0.211 - 2.20
Last Trade Time Type Quantity Stock Price Currency
19:59:20 formt 200 $ 0.87 USD

Diffusion Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 55.68M 64.00M 63.92M $ - $ - -1.79 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Diffusion Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical DFFN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.841.020.83150.93194241,255,9560.033.57%
1 Month1.121.500.750.92803641,405,984-0.25-22.32%
3 Months1.001.700.751.122,379,677-0.13-13.0%
6 Months0.301.890.250.85642125,308,8890.57190.0%
1 Year2.032.200.2110.71851924,040,968-1.16-57.14%
3 Years25.8044.550.2112.211,616,694-24.93-96.63%
5 Years15.45232.500.2114.391,063,615-14.58-94.37%

Diffusion Pharmaceuticals Description

Diffusion Pharmaceuticals Inc is a clinical stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM); Phase II pancreatic cancer; and metastatic brain cancer.

Your Recent History
Diffusion ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.